Attenuated human parainfluenza virus type 1 expressing the respiratory syncytial virus (RSV) fusion (F) glycoprotein from an added gene: Effects of prefusion stabilization and packaging of RSV F

Journal of Virology

Volumn 91, Issue 22, 2017, Pages

  Liu, Xiang ^a   Liang, Bo ^a   Ngwut, Joan ^a   Liu, Xueqiao ^a   Surman, Sonja ^a   Lingemann, Matthias ^a,b   Kwong, Peter D ^a   Graham, Barney S ^a   Collins, Peter L ^a   Munir, Shirin ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b TECHNICAL UNIVERSITY OF BRAUNSCHWEIG   (Germany)

Author keywords

Human parainfluenza virus type 1; Intranasal vaccine; Live attenuated vaccine; Mucosal vaccines; Pediatric vaccine; Prefusion F; Respiratory syncytial virus; Vaccine

Indexed keywords

LIVE VACCINE; NEUTRALIZING ANTIBODY; PARAINFLUENZA VACCINE; RESPIRATORY SYNCYTIAL VIRUS VACCINE; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VECTOR; RECOMBINANT PROTEIN; VIRUS ANTIBODY;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; DISULFIDE BOND; EMBRYO; F GENE; HUMAN; HUMAN CELL; HUMAN PARAINFLUENZA VIRUS 1; HUMAN RESPIRATORY SYNCYTIAL VIRUS; HYDROPHOBICITY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MUTATION; NONHUMAN; PARAINFLUENZA VIRUS INFECTION; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN MODIFICATION; PROTEIN STABILITY; PROTEIN STRUCTURE; RESPIRATORY SYNCYTIAL VIRUS INFECTION; SYRIAN HAMSTER; VACCINE PRODUCTION; VIRAL GENETICS; VIROGENESIS; VIRUS ATTENUATION; VIRUS GENE; ANIMAL; CHLOROCEBUS AETHIOPS; GENE EXPRESSION; GENE VECTOR; GENETICS; GUINEA PIG; IMMUNOLOGY; MESOCRICETUS; PHYSIOLOGY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; VERO CELL LINE; VIRUS ASSEMBLY;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; GENE EXPRESSION; GENETIC VECTORS; GUINEA PIGS; HUMANS; MESOCRICETUS; PARAINFLUENZA VIRUS 1, HUMAN; RECOMBINANT PROTEINS; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUSES; VERO CELLS; VIRAL FUSION PROTEINS; VIRUS ASSEMBLY;

EID: 85032277462     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01101-17     Document Type: Article

References (40)

1. Afonso CL, Amarasinghe GK, Banyai K, Bao Y, Basler CF, Bavari S, Bejerman N, Blasdell KR, Briand FX, Briese T, Bukreyev A, Calisher CH, Chandran K, Cheng J, Clawson AN, Collins PL, Dietzgen RG, Dolnik O, Domier LL, Durrwald R, Dye JM, Easton AJ, Ebihara H, Farkas SL, Freitas-Astua J, et al. 2016. Taxonomy of the order Mononegavirales: update 2016. Arch Virol 161:2351-2360. https://doi.org/10.1007/s00705-016-2880-1.
2. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. https://doi.org/10.1016/S0140-6736(10)60206-1.
3. Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY, Alvarado M, Anderson HR, Anderson LM, Andrews KG, Atkinson C, Baddour LM, Barker-Collo S, Bartels DH, et al. 2012. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 380:2095-2128. https://doi.org/10.1016/ S0140-6736(12)61728-0.
4. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. 2012. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 31:5-9. https://doi.org/10.1097/INF.0b013e31822e68e6.
5. Kapikian AZ, Mitchell RH, Chanock RM, Shvedoff RA, Stewart CE. 1969. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89:405-421. https://doi.org/10.1093/ oxfordjournals.aje.a120954.
6. Ottolini MG, Porter DD, Hemming VG, Prince GA. 2000. Enhanced pulmonary pathology in cotton rats upon challenge after immunization with inactivated parainfluenza virus 3 vaccines. Viral Immunol 13: 231-236. https://doi.org/10.1089/vim.2000.13.231.
7. Murphy BR, Sotnikov AV, Lawrence LA, Banks SM, Prince GA. 1990. Enhanced pulmonary histopathology is observed in cotton rats immunized with formalin-inactivated respiratory syncytial virus (RSV) or purified F glycoprotein and challenged with RSV 3 to 6 months after immunization. Vaccine 8:497-502. https://doi.org/10.1016/0264-410X(90)90253-I.
8. Bernstein DI, Malkin E, Abughali N, Falloon J, Yi T, Dubovsky F, Investigators M-C. 2012. Phase 1 study of the safety and immunogenicity of a live, attenuated respiratory syncytial virus and parainfluenza virus type 3 vaccine in seronegative children. Pediatr Infect Dis J 31:109-114. https:// doi.org/10.1097/INF.0b013e31823386f1.
9. Karron RA, Luongo C, Thumar B, Loehr KM, Englund JA, Collins PL, Buchholz UJ. 2015. A gene deletion that upregulates viral gene expression yields an attenuated RSV vaccine with improved antibody responses in children. Sci Transl Med 7:312ra175. https://doi.org/10.1126/ scitranslmed.aac8463.
10. Karron RA, Mateo JC, Thumar B, Schaap-Nutt A, Buchholz UJ, Schmidt AC, Bartlett EJ, Murphy BR, Collins PL. 2014. Evaluation of a liveattenuated human parainfluenza type 1 vaccine in adults and children. J Pediatric Infect Dis Soc 4:e143-e146. https://doi.org/10.1093/jpids/ piu104.
11. Wright PF, Karron RA, Belshe RB, Shi JR, Randolph VB, Collins PL, O'Shea AF, Gruber WC, Murphy BR. 2007. The absence of enhanced disease with wild-type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine 25: 7372-7378. https://doi.org/10.1016/j.vaccine.2007.08.014.
12. Bartlett EJ, Cruz AM, Esker J, Castano A, Schomacker H, Surman SR, Hennessey M, Boonyaratanakornkit J, Pickles RJ, Collins PL, Murphy BR, Schmidt AC. 2008. Human parainfluenza virus type 1 C proteins are nonessential proteins that inhibit the host interferon and apoptotic responses and are required for efficient replication in nonhuman primates. J Virol 82:8965-8977. https://doi.org/10.1128/JVI.00853-08.
13. Liljeroos L, Krzyzaniak MA, Helenius A, Butcher SJ. 2013. Architecture of respiratory syncytial virus revealed by electron cryotomography. Proc Natl Acad Sci U S A 110:11133-11138. https://doi.org/10.1073/pnas.1309070110.
14. McLellan JS, Chen M, Leung S, Graepel KW, Du X, Yang Y, Zhou T, Baxa U, Yasuda E, Beaumont T, Kumar A, Modjarrad K, Zheng Z, Zhao M, Xia N, Kwong PD, Graham BS. 2013. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340: 1113-1117. https://doi.org/10.1126/science.1234914.
15. McLellan JS, Chen M, Joyce MG, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Chen L, Srivatsan S, Zheng A, Zhou T, Graepel KW, Kumar A, Moin S, Boyington JC, Chuang GY, Soto C, Baxa U, Bakker AQ, Spits H, Beaumont T, Zheng Z, Xia N, Ko SY, Todd JP, Rao S, Graham BS, Kwong PD. 2013. Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus. Science 342:592-598. https://doi.org/10.1126/ science.1243283.
16. Swanson KA, Settembre EC, Shaw CA, Dey AK, Rappuoli R, Mandl CW, Dormitzer PR, Carfi A. 2011. Structural basis for immunization with postfusion respiratory syncytial virus fusion F glycoprotein (RSV F) to elicit high neutralizing antibody titers. Proc Natl Acad Sci U S A 108: 9619-9624. https://doi.org/10.1073/pnas.1106536108.
17. McLellan JS, Yang Y, Graham BS, Kwong PD. 2011. Structure of respiratory syncytial virus fusion glycoprotein in the postfusion conformation reveals preservation of neutralizing epitopes. J Virol 85:7788-7796. https://doi.org/10.1128/JVI.00555-11.
18. Ngwuta JO, Chen M, Modjarrad K, Joyce MG, Kanekiyo M, Kumar A, Yassine HM, Moin SM, Killikelly AM, Chuang GY, Druz A, Georgiev IS, Rundlet EJ, Sastry M, Stewart-Jones GB, Yang Y, Zhang B, Nason MC, Capella C, Peeples ME, Ledgerwood JE, McLellan JS, Kwong PD, Graham BS. 2015. Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera. Sci Transl Med 7:309ra162. https://doi.org/10.1126/scitranslmed.aac4241.
19. Liang B, Munir S, Amaro-Carambot E, Surman S, Mackow N, Yang L, Buchholz UJ, Collins PL, Schaap-Nutt A. 2014. Chimeric bovine/human parainfluenza virus type 3 expressing respiratory syncytial virus (RSV) F glycoprotein: effect of insert position on expression, replication, immunogenicity, stability, and protection against RSV infection. J Virol 88: 4237-4250. https://doi.org/10.1128/JVI.03481-13.
20. Liang B, Ngwuta JO, Herbert R, Swerczek J, Dorward DW, Amaro-Carambot E, Mackow N, Kabatova B, Lingemann M, Surman S, Yang L, Chen M, Moin SM, Kumar A, McLellan JS, Kwong PD, Graham BS, Schaap-Nutt A, Collins PL, Munir S. 2016. Packaging and prefusion stabilization separately and additively increase the quantity and quality of RSV-neutralizing antibodies induced by respiratory syncytial virus (RSV) fusion protein expressed by a parainfluenza vector. J Virol 90: 10022-10038. https://doi.org/10.1128/JVI.01196-16.
21. Liang B, Surman S, Amaro-Carambot E, Kabatova B, Mackow N, Lingemann M, Yang L, McLellan JS, Graham BS, Kwong PD, Schaap-Nutt A, Collins PL, Munir S. 2015. Enhanced neutralizing antibody response induced by respiratory syncytial virus pre-fusion F protein expressed by a vaccine candidate. J Virol 89:9499-9510. https://doi.org/10.1128/JVI.01373-15.
22. Reed G, Jewett PH, Thompson J, Tollefson S, Wright PF. 1997. Epidemiology and clinical impact of parainfluenza virus infections in otherwise healthy infants and young children <5 years old. J Infect Dis 175: 807-813. https://doi.org/10.1086/513975.
23. Mackow N, Amaro-Carambot E, Liang B, Surman S, Lingemann M, Yang L, Collins PL, Munir S. 2015. Attenuated human parainfluenza virus type 1 (HPIV1) expressing the fusion glycoprotein of human respiratory syncytial virus (RSV) as a bivalent HPIV1/RSV vaccine. J Virol 89:10319-10332. https:// doi.org/10.1128/JVI.01380-15.
24. Bartlett EJ, Castano A, Surman SR, Collins PL, Skiadopoulos MH, Murphy BR. 2007. Attenuation and efficacy of human parainfluenza virus type 1 (HPIV1) vaccine candidates containing stabilized mutations in the P/C and L genes. Virol J 4:67. https://doi.org/10.1186/1743-422X-4-67.
25. Bartlett EJ, Amaro-Carambot E, Surman SR, Collins PL, Murphy BR, Skiadopoulos MH. 2006. Introducing point and deletion mutations into the P/C gene of human parainfluenza virus type 1 (HPIV1) by reverse genetics generates attenuated and efficacious vaccine candidates. Vaccine 24:2674-2684. https://doi.org/10.1016/j.vaccine.2005.10.047.
26. McLellan JS. 2015. Neutralizing epitopes on the respiratory syncytial virus fusion glycoprotein. Curr Opin Virol 11:70-75. https://doi.org/10.1016/j.coviro.2015.03.002.
27. Kwakkenbos MJ, Diehl SA, Yasuda E, Bakker AQ, van Geelen CM, Lukens MV, van Bleek GM, Widjojoatmodjo MN, Bogers WM, Mei H, Radbruch A, Scheeren FA, Spits H, Beaumont T. 2010. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat Med 16:123-128. https://doi.org/10.1038/ nm.2071.
28. Yoder SM, Zhu Y, Ikizler MR, Wright PF. 2004. Role of complement in neutralization of respiratory syncytial virus. J Med Virol 72:688-694. https://doi.org/10.1002/jmv.20046.
29. Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS, WHO Product Development for Vaccines Advisory Committee. 2016. Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015. Vaccine 34:2865-2869. https://doi.org/10.1016/j.vaccine.2016.02.078.
30. Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS, WHO RSV Vaccine Consultation Expert Group. 2016. WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015. Vaccine 34:190-197. https://doi.org/10.1016/j.vaccine.2015.05.093.
31. Durbin AP, Elkins WR, Murphy BR. 2000. African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1,-2, and-3 infection. Vaccine 18:2462-2469. https://doi.org/ 10.1016/S0264-410X(99)00575-7.
32. Buchholz UJ, Finke S, Conzelmann KK. 1999. Generation of bovine respiratory syncytial virus (BRSV) from cDNA: BRSV NS2 is not essential for virus replication in tissue culture, and the human RSV leader region acts as a functional BRSV genome promoter. J Virol 73:251-259.
33. Whitehead SS, Juhasz K, Firestone CY, Collins PL, Murphy BR. 1998. Recombinant respiratory syncytial virus (RSV) bearing a set of mutations from cold-passaged RSV is attenuated in chimpanzees. J Virol 72: 4467-4471.
34. Newman JT, Surman SR, Riggs JM, Hansen CT, Collins PL, Murphy BR, Skiadopoulos MH. 2002. Sequence analysis of the Washington/1964 strain of human parainfluenza virus type 1 (HPIV1) and recovery and characterization of wild-type recombinant HPIV1 produced by reverse genetics. Virus Genes 24:77-92. https://doi.org/10.1023/A:1014042221888.
35. Kolakofsky D, Pelet T, Garcin D, Hausmann S, Curran J, Roux L. 1998. Paramyxovirus RNA synthesis and the requirement for hexamer genome length: the rule of six revisited. J Virol 72:891-899.
36. Clements ML, Belshe RB, King J, Newman F, Westblom TU, Tierney EL, London WT, Murphy BR. 1991. Evaluation of bovine, cold-adapted human, and wild-type human parainfluenza type 3 viruses in adult volunteers and in chimpanzees. J Clin Microbiol 29:1175-1182.
37. Coates HV, Alling DW, Chanock RM. 1966. An antigenic analysis of respiratory syncytial virus isolates by a plaque reduction neutralization test. Am J Epidemiol 83:299-313. https://doi.org/10.1093/oxfordjournals.aje.a120586.
38. Munir S, Le Nouen C, Luongo C, Buchholz UJ, Collins PL, Bukreyev A. 2008. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J Virol 82:8780-8796. https:// doi.org/10.1128/JVI.00630-08.
39. Luongo C, Winter CC, Collins PL, Buchholz UJ. 2013. Respiratory syncytial virus modified by deletions of the NS2 gene and amino acid S1313 of the L polymerase protein is a temperature-sensitive, live-attenuated vaccine candidate that is phenotypically stable at physiological temperature. J Virol 87:1985-1996. https://doi.org/10.1128/JVI.02769-12.
40. Bartlett EJ, Amaro-Carambot E, Surman SR, Newman JT, Collins PL, Murphy BR, Skiadopoulos MH. 2005. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys. Vaccine 23:4631-4646. https://doi.org/ 10.1016/j.vaccine.2005.04.035.